Ironwood Pharmaceuticals Inc - Class A

Research Ironwood Pharmaceuticals Inc - Class A (IRWD) on Bullrun: valuation model: 21.1% undervalued, market cap USD 707.84M, P/E 7.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerIRWD
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic
CurrencyUSD
Valuation signal21.1% undervalued
Market capUSD 707.84M
P/E7.2
Financial periodFY2025
RevenueUSD 296.15M
Revenue growth-15.7%
Net incomeUSD 24.02M
Free cash flowUSD 127.01M

Valuation Snapshot

Bullrun's latest valuation model marks Ironwood Pharmaceuticals Inc - Class A as 21.1% undervalued; latest market cap is USD 707.84M; P/E is 7.2.

About Ironwood Pharmaceuticals Inc - Class A

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.

Frequently asked questions

Is Ironwood Pharmaceuticals Inc - Class A overvalued or undervalued?

Bullrun's valuation model currently marks Ironwood Pharmaceuticals Inc - Class A as 21.1% undervalued.

What is Ironwood Pharmaceuticals Inc - Class A's market cap?

Ironwood Pharmaceuticals Inc - Class A's market capitalization is USD 707.84M.

What is Ironwood Pharmaceuticals Inc - Class A's P/E ratio?

Ironwood Pharmaceuticals Inc - Class A's price-to-earnings (P/E) ratio is 7.2.